Researchers at Oregon Health & Science University report that a rare genetic change, known as the Christchurch mutation of the APOE gene, may protect against Parkinson's disease and Lewy body dementia. The findings were published in the journal Cell Reports. The study is the first to link this mutation to Parkinson's specifically.
The mutation was first identified in New Zealand. Earlier work, beginning with a 2019 case of a woman from Colombia who carried it, found that the mutation seemed to delay dementia symptoms in people who were otherwise genetically destined to develop Alzheimer's disease. Animal studies had also shown that the mutation prevents the tau protein, which is tied to Alzheimer's, from accumulating in the brain.
The new work confirmed that effect on tau and extended it. The researchers used mouse models predisposed to build up both tau and alpha-synuclein, the protein that characterizes Parkinson's and Lewy body dementia. Mice carrying the Christchurch mutation did not accumulate either protein in the brain, despite their predisposition. In effect, the mutation appeared to shield the brain from the buildup of proteins thought to drive both Alzheimer's and Parkinson's.
Why this matters is partly about direction. Gene therapies are already being developed around a more common APOE variant, APOE-2, which also appears protective against Alzheimer's. Senior author Unni said the Christchurch mutation seems even more protective than APOE-2, acting like a "super-APOE-2" in the mouse model studied. His lab is seeking grant funding to extend preclinical work, with the aim of eventually persuading drug companies to invest in clinical trials of APOE Christchurch gene therapy in people.
The research began with awards from OHSU's Oregon Alzheimer's Disease Research Center and Parkinson Center, and from the American Parkinson Disease Association and Stop Alzheimer's Now. Lead author Carlos Soto-Faguas, a postdoctoral researcher in Unni's lab, is among the co-authors.